Owing to high prevalence of arterial hypertension (AH) and allergic rhinitis (AR), these diseases frequently coexist. The study aimed to assess whether improvement of AR by conventional treatment can improve blood pressure (BP) control in this population. Sixtyeight subjects of both sexes aged 35-60 years with AR and AH were randomized into two groups to receive in addition to their antihypertensive medications: treatment group (n ¼ 34) Fluticasone nasal 50 lg/spray b.i.d. and Fenoxifenadine 180 mg tablets q.d., and control group (n ¼ 34) 0.9% NaCl nasal drops b.i.d. Office BP and AR severity (using the Relative Quality of Life Questionnaire (RQLQ)) and high-sensitive C-reactive protein (hs-CRP) were measured at study entry and after 8 weeks in both groups, without changing of antihypertensive medications. In Treatment group an improvement in RQLQ, significant reduction of systolic BP (SBP) (DSBP 7.474.3 mm Hg, P ¼ 0.006) and reduction of hs-CRP level (DCRP 2.0571.08; P ¼ 0.028) were observed, whereas diastolic BP (DBP) remained unchanged (DDBP 0.971.7 mm Hg, P ¼ 0.7). There was a significant correlation between DRQLQ and DSBP (r ¼ 0.86; P ¼ 0.019) and between DCRP and DSBP (r ¼ 0.56; P ¼ 0.027). No statistically significant changes of RQLQ, BP and CRP were observed in the control group. In patients with coincidence of AH and AR, medications meant to improve AR attenuate low-grade systemic inflammation and can lower SBP, but not DBP.
Introduction
Approximately 25% of the population living in industrialized countries suffers from both rhinitis and hypertension. 1, 2 In Israel, the prevalence of allergic rhinitis (AR) among the adult population is 14% 3 and the prevalence of arterial hypertension (AH) is approximately 25%. 4 Therefore, it is not surprising to find comorbidity of these two common diseases. There is a controversy regarding the relationship between AR and AH. In a relatively small study group of 330 adults, Kony et al., 5 found an association between AR and systolic blood pressure (SBP), observed only in women. These results were confirmed by Peppard and Yang's letter. 6 However, Dahl et al. 7 using data of 9134 individuals from the Danish general population, could not confirm the results of previous studies. Nevertheless, the impact of treatment of AR on AH is a fascinating topic. Recently, a large amount of information has been collected on vascular inflammation in AH, indicating that inflammation may be involved in the initiation as well as in the development of AH, thus allowing us to reconsider the pathogenic mechanisms of AH. 8 The association between inflammation and AH resembles a similar association between low-grade inflammation and other components of the metabolic syndrome, endothelial dysfunction as well as increased serum levels of C-reactive protein (CRP) in patients with AH. [9] [10] [11] Greater plasma CRP concentrations were found in patients with AH in comparison to normotensive healthy controls, independently of the confounding influence of several CRPs. 12, 13 Elevated CRP levels, a marker of chronic inflammation, has been associated with AH 13 and pre-hypertension. 14 Moreover, other proinflammatory cytokines (tumour-necrosis factora and interleukin (IL)-6) were found to be independent risk factors for AH in apparently healthy subjects. 15 The aim of this study was to examine whether conventional treatment of AR can influence blood pressure (BP) control of patients suffering from both AR and AH and whether there is any correlation between CRP concentrations BP in these patients. Data were collected in primary care and allergy  clinics in the city of Ashdod in Israel, between  March 2001 and April 2005. A primary care physician and/or allergy specialist selected 68 subjects aged 25-60 years, in whom both AH and AR were diagnosed previously or at referral. Exclusion criteria were as follows: (1) any modification of antihypertensive treatment during the month before randomization; (2) recent upper or lower respiratory tract infection; (3) persistent bronchial asthma of any degree; (4) forced expiratory volume in 1 s o80%; (5) any rheumatologic disease; (6) malignancy and (7) body mass index (BMI) 431 kg/m 2 . Patients were randomized to two groups: (1) treatment group (n ¼ 34), which in addition to their antihypertensive treatment received conventional treatment for AR consisting of H1 blocker and intranasal steroid and (2) control group (n ¼ 34), which in addition to their antihypertensive treatment received intranasal NaCl 0.9% drops only. Blood samples were obtained from all patients and analysed for serum high-sensitive C-reactive protein (Hs-CRP). BP was measured using an automatic electronic sphygmomanometer (OMRON M4; OM-RON MATSUSAKA Co. Ltd, Japan) following a 5-min rest in sitting position. Two consecutive BP measurements were performed and a mean of the two measurements was used to define SBP and DBP.
Methods

Study participants
Body height and weight measurements were obtained with the subjects wearing light clothing, without shoes. BMI (weight/height 2 (kg/m 2 ) was calculated. AR was diagnosed using a set of six questions proposed by the International Study of Asthma and Allergies in Childhood, 16 validated for adults 17 and using skin prick tests. The patients in the treatment group received Fluticasone (Flixonase, GlaxoSmithKline, Agis Industries Ltd, Israel) nasal 50 mg/spray (one puff in each nostril morning and evening, and Fenoxifenadine 180 mg tablets (Telfast, Aventis Pharmaceuticals, Sanofy-Aventis Ltd, Israel) one tablet each evening (1/day)) for a period of 8 weeks. Patients in the control group received 2 drops of 0.9% (w/v) sodium chloride (B/Braun Melsungen AG, Melsungen, Germany) in each nostril two times a day. The use of nonsteroidal anti-inflammatory medications (NSAIDs), systemic corticosteroids and sympathomimetic medications was not permitted from 2 weeks before the study until its end. Patients were assessed at the beginning and at the end of treatment. The Relative Quality of Life Questionnaire (RQLQ) was used just before initial treatment for baseline analysis and after 8 weeks of continuous treatment. The selfadministered study questionnaire RQLQ is a validated instrument used to assess the improvement in the quality of life (QOL) of test subjects. 18 The scoring methodologies for the RQLQ have been previously described by Juniper et al. 17 Briefly, patients scored individual domain of the RQLQ on a five-point symptom scale (0 ¼ not affected, 
Overall RQLQ score was calculated as the average of the seven separate domains. A higher score indicated a greater degree of impairment, whereas a negative change from baseline (i.e. lower score) indicated improvement. Plasma levels of Hs-CRP were measured by immunonephelometry using BN systems (Dade Behring, Marburg, Germany) and the reference interval for Hs-CRP was 1-3 mg/l.
Statistical analysis
All data were expressed as the mean7s.d. Repeated measures analysis of variance was performed to compare differences between the groups as appropriate. Pearson's correlation coefficient r was calculated between changes of BP, RQLQ score and CRP levels. Statistical analyses were performed using the Statistica 6 program for Windows (StatSoft Inc., Tulsa, OK, USA). A value of Po0.05 was considered statistically significant.
Results
The two groups were compared with respect to age, sex, height, weight and duration of history of AR (range 2-50 years) ( Table 1 ). The concomitant medications remained unchanged throughout the study. Nearly all participants were allergic to dust mite allergens, grass pollen and/or olive tree pollen. The mean CRP values of the groups were not significantly different.
Changes in rhinitis symptom score The average RQLQ score at baseline was 2.3270.31 (on a scale of 0-4) in the treatment group, and 2.2770.38 in the control group. The average RQLQ score of participants receiving AR treatment im- Treatment of allergic rhinitis E Magen et al proved to 1.2670.14 (Po0.001) after an 8-week period, whereas in the control group RQLQ remained unchanged (Table 2) .
Changes in BP
In the treatment group, the baseline SBP and diastolic BP (DBP) were 154.575.8 and 87.57 6.3 mm Hg, respectively. After 8 weeks, SBP decreased significantly (DSBP 7.474.3 mm Hg, P ¼ 0.006) (Figure 1 ), whereas DBP remained unchanged (DDBP 0.971.8 mm Hg, P ¼ 0.72) (Figure 2 ). There was a significant positive correlation between DRQLQ and DSBP (r ¼ 0.86; P ¼ 0.019). In the control group, the baseline SBP and DBP were 156.476.1 and 85.874.6 mm Hg, respectively. No statistically significant changes of SBP and DBP were observed in the control group after 8 weeks of AR treatment (Figures 1 and 2) . No difference between men and women in the reduction of SBP and DBP was observed in both study groups. Total cholesterol, low-density lipoprotein, glucose and creatinine remained unaltered in both groups throughout the study.
Changes in Hs-CRP
In the treatment group, a reduction in Hs-CRP levels (DCRP 2.0571.08; P ¼ 0.028) was observed following 8 weeks of AR treatment. There were significant positive correlations between DSBP and DCRP (r ¼ 0.56; P ¼ 0.027) and between DRQLQ and DCRP (r ¼ 0.39; P ¼ 0.011). No statistically significant changes of Hs-CRP were observed in the control group (Table 3) .
Discussion
The main finding of this study is that in patients with comorbidity of AH and AR, treatment of AR can lower SBP. To our knowledge, no previous studies have been performed, which examine the link between treatment of AR and BP control in hypertensive subjects with AR. In our study, both treatment and control group participants had wellmatched severity of AR, nasal symptoms and plasma Hs-CRP levels at entry. Nevertheless, SBP reduction was observed only in the treatment group and its reduction was positively correlated with a reduction in plasma Hs-CRP levels and RQLQ score.
AH is recognized as a multi-factorial disease resulting from the combined effect of environmental and genetic factors. Recently, a large amount of information has been collected on vascular inflammation, indicating that inflammation may be involved in the initiation as well as in the development of AH. 8 We measured plasma concentrations of Hs-CRP and used it as a marker of low-grade inflammation. In participants with Hs-CRP levels 43 mg/l at study entry, a reduction of Hs-CRP was positively correlated with a reduction in SBP. It is well recognized that SBP, pulsatility index and resistance index are used as markers of peripheral vascular resistance. As such, these parameters are independently associated with Hs-CRP and with atherosclerosis and inflammation in hypertensive patients. 19 Moreover, elevation of SBP is associated with arterial stiffening and is correlated with aortic and brachial pulse wave velocity as well as with levels of inflammation. 20 Hs-CRP elevation also predicts pulse pressure reduction in hypertensive subjects. 21 Like AH, AR is part of a systemic disease complex. 22 In patients with AR, allergen-triggered early and late inflammatory responses are associated with elevations of proinflammatory mediators, including cysteinyl leukotrienes, cationic proteins, eosinophil peroxidase, major basic proteins and cytokines, such as IL-3, IL-5, granulocyte-macrophage colony-stimulating factor and IL-13. 23 CRP and IL-6 levels are not simple surrogate markers for histamine or tryptase release by mast cells, nor basophils in acute allergic reactions. Rather, increased levels of CRP and IL-6 characterize a latephase response in allergic reactions. 24 Taking into account the positive correlation between SBP reduction and Hs-CRP, it can be speculated that systemic low-grade inflammation caused by AR worsened BP control by aggravating pre-existing systemic low-grade inflammation and arterial stiffening in AH.
The study, nevertheless, has some methodological limitations. Firstly, the results are restricted, as the study was not a double-blind placebo-controlled trial. In addition, although the complete study lasted a whole year, the intervention and follow-up of each subject lasted only 8 weeks. Consequently, it is difficult to ascertain precisely what effect, if any, seasonal variation of AR would have on AH. Nonetheless, it is reasonable to assume that in participants sensitive to outdoor allergens, seasonal exacerbation of AR could influence BP. Secondly, the correlation between Hs-CRP reduction and SBP was found in participants with CRP 43 mg/l, a point that may limit the generalizability of the finding. Thirdly, although inflammation may provide an important link between AR treatment and SBP reduction, QOL also improved and there was a Health-related QOL is considered one of the key concepts in contemporary medical practice and delivery of health care. 24, 25 In relation to chronic diseases, such as AH and AR, QOL factors seem to play an additional important role, with several other characteristics, such a BP and drug-related factors. 26 QOL improvement has been targeted in rehabilitation programs among patients with AH, owing to the belief that stress reduction can reduce hypertension. 27 Moreover, some intervention programs for stress reduction are used effectively for BP reduction. [27] [28] [29] [30] It is well known that patients with AH tend to underestimate the impact of their condition on QOL, 31 ,32 yet in several studies an improvement of QOL had been noted to cause BP reduction. [33] [34] [35] [36] [37] In AH, BP control was shown to be related to a sense of general well being and to measures of physical health status, that is, physical symptom incidence and sleep dysfunction. 36 Our study further confirms these previous observations, showing that an improvement of QOL must be an important part of the non-pharmacological and pharmacological interventions in the treatment of AH.
